Annabel Samimy: And do you dare to venture what market share could be at this point?
David Moatazedi: Yes. As far as market share last quarter, we estimated that we had captured about 11% of the market. We don’t expect to click up a full share point every quarter. clearly, we gained share in the third quarter. And so I think we’re approaching a share point higher, and we’ll certainly give you an update when we feel confident that we would collect study 1 share.
Annabel Samimy: Okay. And then 1 other question. To what extent do you say, I mean, obviously, you guys have done a really good job penetrating accounts. To what extent do you think Evolysse is going to boost additional account penetration, how many accounts do you think are out there who do not entertain the use of Jeuveau just because you don’t have, I guess, a portfolio of products to offer them.
David Moatazedi: We believe that with Jeuveau alone, we can continue to expand our market penetration. And I think when you look back over the last 3 years, our penetration of new accounts has accelerated over the last month 12 months prior. So we believe that accounts are more interested in bringing us on today than we were in a position a year or 2 years prior. So Evolysse is certainly a catalyst in the sense that it becomes more interesting to partner with us on a broader portfolio. But we do believe that we have an excellent runway of existing accounts with just Jeuveau and Evolysse gives us an opportunity to offer our existing customer base, which now exceeds 11,000 customers, the opportunity to expand their portfolio offering with us, which is something that we’ve consistently heard from our customers is that they like our cash pay positioning, they like our investment in advertising that happens to co-branded media.
And to the extent that we could extend that offering to the filler line, that would give them more reasons to want to partner with us across the portfolio of products. So for that reason, we’re very optimistic about what Evolysse could bring when we introduce it to the market. Of course, we still have some time until we launched Evolysse in 2025. Until then, we see just a tremendous amount of runway for Jeuveau and continued market opportunity.
Operator: Our next question comes from the line of Marc Goodman with SVB Securities.
Marc Goodman: David, what is your sense that the market grew this past quarter? Do you think it was high single digits? It just seemed obviously, BOTOX grew 5%, right? I mean — and then secondly, what are your thoughts about Revance and the dynamics of what they’ve done and their metrics so far? .
David Moatazedi: Marc, we’re really pleased to see that the third quarter reflected a really healthy rebound in terms of procedural volume. It’s hard to pin the exact number, but we do believe this is a high single-digit growth market coming into this year. And I think overall, our views are relatively intact and Q3 was certainly an acceleration of market growth from the front half of the year, which is positive. And we’re assuming that carry through into the fourth quarter. We have no reason to believe that it wouldn’t. And just keep in mind that that’s been the traditional growth rate for this market over many years. As far as the market dynamics of competitors, we continue to maintain our focus on our brand positioning and establishing this brand in the market as a unique beauty product.
And I think that’s differentiated us from the existing competitors that competes on similar dynamics that other drug companies do. And I think we’ll continue to do that. I don’t have a view to share on how other companies that are launching are coming along. I think we’ll get a view from that when they report there.
Operator: Our next question comes from the line of Doug Tsao with H.C. Wainwright.
Douglas Tsao: And congrats on the progress. Just on the extra-strength, I’m just curious, do you have a thought or perspective on the amount of sort of extended duration is a function of just more top in versus the hyper concentration? Or I mean, is the hyperconcentration important? Or is it just simply just more toxin? .
